European Pharmaceutical Review

MARCH 6, 2024

The US Food and Drug Administration (FDA) has approved the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. The approval is also accompanied by labelling with safety warnings.

Food and Drug Administration 91

Food and Drug Administration Medicine FDA Food 91

World of DTC Marketing

APRIL 12, 2021

The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. Coupled with all this is the continued outsourcing of raw materials and other steps in drug development. We need a 21st-century approach that puts patient safety first.

Food and Drug Administration 187

Food and Drug Administration Prescription Pharma Manufacturing 187

European Pharmaceutical Review

OCTOBER 25, 2023

The document by the Medicines and Healthcare products Regulatory Agency (MHRA), US Food and Drug Administration (FDA) and Health Canada, contains key guidance on predetermined change control plans (PCCPs) for MLMDs. The device may be reassessed to ensure the performance and safety of the device is negatively impacted.

Medical 92

Medical Food and Drug Administration Manufacturing Safety 92

European Pharmaceutical Review

MARCH 13, 2024

FDA inspections Identification of data integrity deviations Of the 70 Warning Letters issued by the US Food and Drug Administration (FDA) so far in 2024, three have identified data integrity issues at pharmaceutical manufacturing sites outside the US. In a letter issued to China-based Sichuan Deebio Pharmaceutical Co.

FDA 91

FDA Food and Drug Administration Manufacturing Pharmaceutical manufacturing 91

European Pharmaceutical Review

FEBRUARY 19, 2024

However, by the very nature of TILs, we have years of data demonstrating them to be more successful for these cancer types,” Dr Jason Bock, CEO of the Cell Therapy Manufacturing Center (CTMC) in the US commented. So far, we haven’t seen great success from CAR-T or other cell therapies in treating patients with solid tumours. percent, 47.8

Food and Drug Administration 73

Food and Drug Administration FDA Manufacturing Food 73

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Food and Drug Administration 106

Food and Drug Administration Side effects Pharmaceutical Leads 106

European Pharmaceutical Review

MARCH 4, 2024

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Food and Drug Administration 90

Food and Drug Administration Transportation FDA Medical 90

European Pharmaceutical Review

AUGUST 31, 2023

In addition, radionuclide therapy has the potential to achieve high efficacy rates since the administered drugs spare surrounding healthy tissue, thus, reducing the burden on the patient. 1-4 Besides these drug products, several companies worldwide are developing radiotheranostics in clinical trials built on various radionuclides.

Food and Drug Administration 80

Food and Drug Administration Manufacturing Safety Transportation 80

European Pharmaceutical Review

DECEMBER 21, 2022

Most psychedelic drugs are Schedule I controlled substances, which means that very strict legal and regulatory controls accompany their use” Some psychedelics originate in nature and have been used by Indigenous cultures for thousands of years; others are manipulated or manufactured.

Food and Drug Administration 109

Food and Drug Administration Medicine Food Government 109

European Pharmaceutical Review

JUNE 29, 2023

Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. 1 Nitrosamines are not new or unknown impurities.

Food and Drug Administration 87

Food and Drug Administration Manufacturing Food Medicine 87

European Pharmaceutical Review

DECEMBER 13, 2022

The World Health Organization (WHO) linked this recent incident to an Indian manufacturer, saying that the cough syrups contained “unacceptable amounts of diethylene glycol and ethylene glycol”. This was also the first step on the road towards universal adoption of good manufacturing practice (GMP).

Food and Drug Administration 94

Food and Drug Administration Manufacturing Safety Food 94

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 52

Manufacturing Food and Drug Administration FDA Marketing 52

Pharma Leaders

MAY 1, 2023

The US Food & Drug Administration (FDA) has declined to approve Ascendis Pharma’s New Drug Application (NDA) for TransCon PTH (palopegteriparatide) to treat hypoparathyroidism in adult patients. The FDA also did not request for new preclinical or Phase III clinical trials for assessing efficacy or safety.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Food 52

Pharmaceutical Technology

JUNE 13, 2023

The US Food and Drug Administration (FDA) has approved Neobiosis’ investigational new drug (IND) application for ViXome to treat post-Covid-19 syndrome (also known as long Covid). The company stated that the Phase I/IIa trial will thoroughly evaluate the therapy’s clinical efficacy and safety.

Food and Drug Administration 59

Food and Drug Administration FDA Food Safety 59

European Pharmaceutical Review

JUNE 29, 2023

The US Food and Drug Administration (FDA) has approved Lantidra, the first cell therapy for certain adults with Type 1 diabetes. Lonza and Vertex to partner to manufacture diabetes cell therapies The post First cell therapy approved for Type 1 diabetes appeared first on European Pharmaceutical Review.

Food and Drug Administration 95

Food and Drug Administration FDA Food Education 95

Pharmaceutical Technology

JUNE 14, 2023

The agreement covers rights for the development, manufacture and commercialisation of NOV03 in the country. The therapy has shown efficacy and safety in trials for patients with a history of dry eye disease and clinical Meibomian gland dysfunction. to treat dry eye disease.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Safety Prescription 52

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The vaccine showed an encouraging safety and tolerability profile in both trials.

Food and Drug Administration 105

Food and Drug Administration FDA Engineering Food 105

European Pharmaceutical Review

AUGUST 16, 2022

The Phase III RATIONALE 301 study evaluated the efficacy and safety of tislelizumab versus sorafenib as a first-line systemic treatment in participants with unresectable hepatocellular carcinoma. . In addition, the safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported.

Food and Drug Administration 98

Food and Drug Administration Patients Safety Food 98

World of DTC Marketing

APRIL 15, 2021

In some instances, vaccine-hesitant activists are manufacturing stories of deaths related to the vaccine that never happened. Also cited was a lack of trust in the government to ensure the vaccines’ safety and effectiveness. The major concerns for hesitancy included worries over side effects and that the vaccine is too new.

Food and Drug Administration 203

Food and Drug Administration Government Safety Side effects 203

European Pharmaceutical Review

NOVEMBER 15, 2022

The validation of computerized systems should be focused on ‘intended use’ and scaled commensurate with the risks to patient safety, product quality and data integrity” The focus until now has too often been on compliance and not on quality. Takeaways from ISPE’s GAMP 5 Second Edition update.

Manufacturing 86

Manufacturing Pharma Food and Drug Administration Safety 86

Pharmaceutical Technology

JUNE 30, 2022

This deal might comprise Omicron-adapted Covid-19 vaccines for use in adults, contingent on obtaining the US Food and Drug Administration (FDA) authorisation. Last week, the companies reported findings where two Omicron-adapted vaccine candidates showed safety, tolerability and immunogenicity.

Government 98

Government Food and Drug Administration FDA Food 98

European Pharmaceutical Review

SEPTEMBER 25, 2023

Moreover, the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC. The FDA’s target action date is the second half of 2024. months for TEVIMBRA versus 6.3

Food and Drug Administration 91

Food and Drug Administration Manufacturing Safety Medicine 91

European Pharmaceutical Review

JANUARY 29, 2024

1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way to resolution.

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Medicine FDA 98

European Pharmaceutical Review

AUGUST 28, 2023

Potential of inclisiran for lowering LDL-C These findings “reconfirm and extend prior observations about the safety profile and efficacy of inclisiran for people with ASCVD and those at risk of cardiovascular disease, in whom cholesterol levels are not adequately controlled,” Dr Ray explained.

Food and Drug Administration 97

Food and Drug Administration Consulting Patients Food 97

Pharmaceutical Technology

SEPTEMBER 27, 2022

Pfizer and BioNTech have submitted an application seeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a 10µg booster of their Omicron BA.4/BA.5-adapted 1-adapted vaccine’s safety and immunogenicity findings, non-clinical and manufacturing data of 10µg bivalent Omicron BA.4/BA.5-adapted

Food and Drug Administration 59

Food and Drug Administration Safety FDA Food 59

PM360

MAY 25, 2023

The new Food and Drug Administration (FDA)’s Decentralized Clinical Trial Draft Guidance issued May 1 st has started to outline guidelines for increased oversight and planning while simultaneously supporting broader DCT adoption. home health visits).

FDA 104

FDA Food and Drug Administration Safety Medicine 104

European Pharmaceutical Review

MAY 29, 2023

Recently, the European Medicines Agency (EMA) took the lead in pushing for process improvements using technologies already established in other manufacturing sectors. Despite this, only 13 nanomedicines had been approved by the US Food and Drug Administration (FDA) before 2015. Tanzini et al.

Food and Drug Administration 73

Food and Drug Administration Manufacturing Pharma Pharmaceutical 73

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

pharmaphorum

DECEMBER 9, 2022

The achievement of the primary endpoint (PDF) milestone triggers a $35 million payment from Blackstone Life Sciences, Autolus also announcing an additional $35 million from Blackstone as a result of the completion of planned activities supporting the obe-cel manufacturing process. months) to the data observed in the prior ALLCAR19 study.

Food and Drug Administration 77

Food and Drug Administration Safety Biopharma Patients 77

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Medicine 107

Medicine Food and Drug Administration Transportation Distribution 107

European Pharmaceutical Review

OCTOBER 21, 2022

At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs). It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series. A two-dose version of the vaccine was approved by the US Food and Drug Administration (FDA) in 2017.

Patients 76

Patients Food and Drug Administration Side effects Food 76

Pharmaceutical Technology

AUGUST 23, 2022

Pfizer and BioNTech have filed an application seeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a booster dosage of an Omicron BA.4/BA.5-adapted The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution.

FDA 52

FDA Food and Drug Administration Distribution Manufacturing 52

European Pharmaceutical Review

JULY 13, 2023

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.

Medical 87

Medical Food and Drug Administration Pharmacology Medicine 87

Pharmaceutical Technology

AUGUST 17, 2008

Nicola Boyes: The FDA has come under criticism recently for extreme delays in approving new drugs for the market, is the criticism valid and if so how are the delays impacting on the US pharmaceutical industry at present? This higher threshold, although not explicit, would also be expected to slow drug approvals.

Food and Drug Administration 52

Food and Drug Administration Food FDA Safety 52

PM360

OCTOBER 28, 2022

Shepherding a new drug to market is a long, expensive, and uncertain process. billion dollars to bring a new drug from discovery to regulatory approval and market launch. Approval success rates of drug candidates are between 10%–20% in the United States, the European Union, and Japan. in 2010 to only 1.9%

Pharma 105

Pharma Food and Drug Administration Government Medicine 105

Legacy MEDSearch

JUNE 30, 2023

Food and Drug Administration (“FDA”) for Cresilon Hemostatic Gel (“CHG ”). ” CHG leverages Cresilon’s in-house manufacturing capabilities, advanced engineering, and focused research teams. For additional important safety information, please see the CHG Instructions For Use.

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

Legacy MEDSearch

JULY 10, 2023

Food and Drug Administration for the use of its FREEDOM60 ® Infusion System with Hizentra ® 50 mL prefilled syringes. “Our studies show up to an 80% reduction in drug preparation tasks for patients using prefilled syringes with the FREEDOM Infusion System as compared to vials.

Medical 40

Medical Food and Drug Administration Recruitment Manufacturing 40